Last reviewed · How we verify
Arm A chemotherapy
Arm A chemotherapy is a Small molecule drug developed by Centro Nacional de Investigaciones Oncologicas CARLOS III. It is currently in Phase 2 development. Also known as: Capecitabine, Cisplatin, Cetuximab, Doxorubicin.
Arm A chemotherapy is used to treat conditions such as bladder cancer, head and neck cancer, and peritoneal malignant mesothelioma, as well as breast cancer and human papilloma virus infection. The specific chemotherapy agents used in Arm A are not explicitly stated in the provided facts, but it is mentioned that Taxotere and Oxaliplatin are interventions in other trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Arm A chemotherapy |
|---|---|
| Also known as | Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil |
| Sponsor | Centro Nacional de Investigaciones Oncologicas CARLOS III |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- DIARRHOEA
- NAUSEA
- ALOPECIA
- FATIGUE
- VOMITING
- ARTHRALGIA
- CONSTIPATION
- ANAEMIA
- STOMATITIS
- MYALGIA
- RASH
- NEUTROPENIA
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm A chemotherapy CI brief — competitive landscape report
- Arm A chemotherapy updates RSS · CI watch RSS
- Centro Nacional de Investigaciones Oncologicas CARLOS III portfolio CI
Frequently asked questions about Arm A chemotherapy
What is Arm A chemotherapy?
Who makes Arm A chemotherapy?
Is Arm A chemotherapy also known as anything else?
What development phase is Arm A chemotherapy in?
What are the side effects of Arm A chemotherapy?
Related
- Manufacturer: Centro Nacional de Investigaciones Oncologicas CARLOS III — full pipeline
- Also known as: Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing